Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Newman

Pediatrics N Chelmsford, MA Doctor of Osteopathy

NPI 1255379475 CMS profile 148058

20 Research Pl Ste 200, Drumhill Pediatrics, N Chelmsford, MA 01863

Open in the dashboard

General payments

$2,529

125 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Newman of N Chelmsford, MA is reported in the CMS Open Payments database as having received $2,529 across 125 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $325 14
2024 General $469 20
2023 General $291 12
2022 General $409 19
2021 General $376 21
2020 General $304 18
2019 General $355 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Newman
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to David Newman were reported at $325. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year David Newman Pediatrics median Middle half National median
2019 $355 $86 $31–$183 $163
2020 $304 $49 $22–$110 $114
2021 $376 $68 $27–$158 $132
2022 $409 $77 $30–$173 $149
2023 $291 $88 $33–$190 $160
2024 $469 $94 $34–$206 $164
2025 $325 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $856 45 payments
  2. Merck Sharp & Dohme Corporation $357 17 payments
  3. GlaxoSmithKline, LLC. $218 10 payments
  4. kaleo, Inc. $190 11 payments
  5. Sanofi Pasteur Inc. $143 7 payments
  6. Ironshore Pharmaceuticals Inc. $98 4 payments
  7. QOL Medical, LLC $87 3 payments
  8. ALK-Abello, Inc $87 4 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $86 4 payments
  10. AstraZeneca Pharmaceuticals LP $86 4 payments
  11. Other $321 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,529 125 payments
Products named General payments · program years 2019–2025
  1. TRUMENBA $821 43 payments
  2. PREVNAR 13 $498 25 payments
  3. GARDASIL 9 $328 15 payments
  4. COMIRNATY $321 13 payments
  5. BEXSERO $218 10 payments
  6. AUVI-Q $190 11 payments
  7. VAXELIS $186 9 payments
  8. PREVNAR 20 $160 7 payments
  9. PREVNAR - 13 $152 9 payments
  10. ROTATEQ $139 7 payments
  11. Other $1,793 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

125 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record